Show simple item record

dc.contributor.authorForment, Josepen
dc.contributor.authorHerzog, Mareikeen
dc.contributor.authorCoates, Juliaen
dc.contributor.authorKonopka, Ten
dc.contributor.authorGapp, BVen
dc.contributor.authorNijman, SMen
dc.contributor.authorAdams, DJen
dc.contributor.authorKeane, TMen
dc.contributor.authorJackson, Stephenen
dc.date.accessioned2016-10-31T11:14:45Z
dc.date.available2016-10-31T11:14:45Z
dc.date.issued2017-01en
dc.identifier.issn1552-4450
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/260961
dc.description.abstractIn model organisms, classical genetic screening via random mutagenesis provides key insights into the molecular bases of genetic interactions, helping to define synthetic lethality, synthetic viability and drug-resistance mechanisms. The limited genetic tractability of diploid mammalian cells, however, precludes this approach. Here, we demonstrate the feasibility of classical genetic screening in mammalian systems by using haploid cells, chemical mutagenesis and next-generation sequencing, providing a new tool to explore mammalian genetic interactions.
dc.description.sponsorshipResearch in the S.P.J. laboratory is funded by Cancer Research UK (CRUK; programme grant C6/A11224), the European Research Council and the European Community Seventh Framework Programme (grant agreement no. HEALTH-F2-2010-259893; DDResponse). Core funding is provided by Cancer Research UK (C6946/A14492) and the Wellcome Trust (WT092096). S.P.J. receives salary from the University of Cambridge, supplemented by CRUK. J.V.F. was funded by Cancer Research UK programme grant C6/A11224 and the Ataxia Telangiectasia Society. J.C. was funded by Cancer Research UK programme grant C6/A11224. D.J.A. is supported by CRUK. Research leading to these results has received funding from the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013) and ERC grant agreement no. (311166).
dc.languageengen
dc.language.isoenen
dc.publisherSpringer Nature
dc.titleGenome-wide genetic screening with chemically mutagenized haploid embryonic stem cells.en
dc.typeArticle
prism.endingPage14
prism.issueIdentifier1en
prism.publicationDate2017en
prism.publicationNameNature Chemical Biologyen
prism.startingPage12
prism.volume13en
dc.identifier.doi10.17863/CAM.6130
dcterms.dateAccepted2016-08-24en
rioxxterms.versionofrecord10.1038/nchembio.2226en
rioxxterms.versionAMen
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2017-01en
dc.contributor.orcidForment, Josep [0000-0002-7797-2583]
dc.contributor.orcidHerzog, Mareike [0000-0001-9747-2327]
dc.contributor.orcidJackson, Stephen [0000-0001-9317-7937]
dc.identifier.eissn1552-4469
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idCancer Research UK (A18796)
pubs.funder-project-idWellcome Trust (092096/Z/10/Z)
pubs.funder-project-idCancer Research UK (A14492)
cam.issuedOnline2016-10-31en
cam.orpheus.successThu Jan 30 12:57:23 GMT 2020 - Embargo updated*
rioxxterms.freetoread.startdate2017-05-01


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record